Trials / Terminated
TerminatedNCT02675439
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Chinook Therapeutics, Inc. (formerly Aduro) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection as a single agent and in combination with ipilimumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADU-S100 | |
| BIOLOGICAL | ipilimumab |
Timeline
- Start date
- 2016-04-28
- Primary completion
- 2019-12-11
- Completion
- 2020-08-06
- First posted
- 2016-02-05
- Last updated
- 2021-12-30
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02675439. Inclusion in this directory is not an endorsement.